TY - JOUR T1 - Treatment outcomes of secondary bacteraemia in patients treated with ceftaroline fosamil: pooled results from six phase III clinical trials. AU - Dryden,Matthew, AU - Kantecki,Michal, AU - Yan,Jean Li, AU - Stone,Gregory G, AU - Leister-Tebbe,Heidi, AU - Wilcox,Mark, Y1 - 2021/12/16/ PY - 2021/04/13/received PY - 2021/10/06/revised PY - 2021/10/30/accepted PY - 2021/12/19/pubmed PY - 2022/5/6/medline PY - 2021/12/18/entrez KW - Bloodstream infection KW - Ceftaroline fosamil KW - Community-acquired pneumonia KW - Complicated skin and soft-tissue infection KW - Secondary bacteraemia SP - 108 EP - 114 JF - Journal of global antimicrobial resistance JO - J Glob Antimicrob Resist VL - 28 N2 - OBJECTIVES: This exploratory pooled analysis assessed the efficacy and safety of ceftaroline fosamil and comparators across six phase III clinical trials in adults with community-acquired pneumonia (CAP) or complicated skin and soft-tissue infection (cSSTI) and secondary bacteraemia. METHODS: In each trial, FOCUS 1 and 2 (CAP), Asia CAP trial, CANVAS 1 and 2 (cSSTI) and COVERS (cSSTI), patients were randomised to ceftaroline fosamil [600 mg q12h by 1-h i.v. infusion, except in COVERS (600 mg q8h by 2-h i.v. infusion), adjusted for renal function] or comparator. Efficacy assessments included clinical and microbiological responses at test-of-cure visit [microbiological modified intent-to-treat (mMITT) population]. Safety outcomes were assessed. RESULTS: The pooled mMITT population comprised 1976 patients, of whom 138 had baseline bacteraemia (ceftaroline fosamil, n = 72; comparator, n = 66). Predominant baseline blood pathogens were Staphylococcus aureus (n = 29), Streptococcus pneumoniae (n = 19) and other streptococci (n = 12). Clinical cure rates in bacteraemic patients were 55/72 (76.4%) and 51/66 (77.3%) for ceftaroline fosamil and comparators, respectively, and in non-bacteraemic patients were 822/966 (85.1%) and 717/872 (82.2%). Favourable microbiological response rates in bacteraemic patients were 56/72 (77.8%) for ceftaroline fosamil and 54/66 (81.8%) for comparators, and in non-bacteraemic patients were 825/966 (85.4%) and 719/872 (82.5%). Adverse events in bacteraemic patients were consistent with the known ceftaroline fosamil safety profile or the underlying indications. CONCLUSION: These pooled clinical and microbiological efficacy data demonstrate generally favourable outcomes for ceftaroline fosamil in patients with CAP or cSSTI and secondary bacteraemia. [Trial Registration: NCT00621504, NCT00509106; NCT01371838; NCT00424190, NCT00423657; NCT01499277]. SN - 2213-7173 UR - https://www.unboundmedicine.com/medline/citation/34922058/Treatment_outcomes_of_secondary_bacteraemia_in_patients_treated_with_ceftaroline_fosamil:_pooled_results_from_six_phase_III_clinical_trials_ DB - PRIME DP - Unbound Medicine ER -